A Phase 1, Open-Label, Single-Sequence Crossover Study in Healthy Male Participants to Determine the Effect of an Inhibitor of Cytochrome P450 3A and P Glycoprotein on Exposure to Orvepitant
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2018
Price : $35 *
At a glance
- Drugs Itraconazole (Primary) ; Orvepitant (Primary)
- Indications Cough; Pruritus
- Focus Pharmacokinetics
- Sponsors NeRRe Therapeutics
- 10 Oct 2018 Status changed from recruiting to completed.
- 11 Jul 2018 Status changed from not yet recruiting to recruiting.
- 29 May 2018 New trial record